Doctor Jeffrey Cummings is world-renowned in the field of Alzheimer's research and he leads UNLV's Center for Transformative Neuroscience.

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...

We have produced resources about lecanemab for you and your patients. Find out more below. Donanemab (brand name Kisunla®) is a new medication used to treat the very early stages of Alzheimer's ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

Lonza Group AG has selected Bank of America Corp. and Centerview Partners to arrange the sale of its capsules and health ...

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

Researchers have devised a way to communicate the effects of taking the new Alzheimer's medications in language that is accessible and understandable to patients and their families. Using data on the ...

The Centres of Excellence are a groundbreaking initiative developed by Alzheimer’s Society to address areas in dementia care that are in urgent need of more research. You are here: Centres of ...